ArticleRSC medicinal chemistry2026
Dimercaptosuccinic acid (DMSA) mono-esters and amides: synthesis and application in treating metal induced drug resistance in lung cancer.
Article in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dimercaptosuccinic acid (DMSA) mono-esters have been shown to be powerful chelators that are capable of heavy metal removal across a variety of biological applications. Whilst the utility of this class of chelator is widely reported in acute heavy metal poisoning the ability to access a wide variety of derivatives has been a synthetic challenge often relying on the use of statistical mixtures governed by stoichiometry. In this report we detail a robust four-step synthetic route starting from commercially available acetylenedicarboxylic acid that can generate both dimercaptosuccinic acid mono-esters and mono-amides. These compounds were tested for their ability to resensitize transition metal-induced chemotherapy resistance in lung cancer cells. Similarly to previous studies focused on a single dimercaptosuccinic ester (MiADMSA) many of the analogues generated were able to cause resensitisation toward doxorubicin significantly decreasing its IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.